The AUTOBIO antibody to hepatitis B surface antigen (Anti-HBs) chemiluminescence immunoassay (CLIA) is intended for the quantitative determination of Anti-HBs concentration in human serum and plasma.
Anti-HBs titer can be determined to monitor the prognosis of patients recovering from the hepatitis B viral infection. It also can be used as an indicator of prior exposure to Hepatitis B viruses. However, it is an immune response index for people who received HBV vaccine.
The antibody response to hepatitis B virus surface antigen (anti-HBs) is an important serological marker for vaccine induced immunity to hepatitis B virus (HBV). An adequate vaccine response is defined as an anti-HBs level of higher than 100IU/l 4 to 8 weeks after the last of three or four vaccine injections. It is widely accepted that a sustained level of at least 10IU/l is protective against HBV infection. Vaccinees withoutsufficient anti-HBs responses, so-called nonresponders or low responders, undergo a special regimen of additional vaccine doses. For liver transplant recipients, quantitative measurement of anti-HBs levels is used in the management of hepatitis B immune globulin prophylaxis, which is initiated to maintain anti-HBs levels of at least 100IU/l or 200IU/l, according to different guidelines.
These are divided into four categories based on Anti-HBs concentration
(I) nonresponders: less than 1mIU/ml
(II) low responders: 1-10mIU/ml
(III) Medium responders: 10-100mIU/ml
(IV) High responders: more than 100mIU/ml
